PET shows early response to hormone therapy in breast cancer

Share this article:

Molecular imaging of progesterone receptor status in breast tumors using positron emission tomography (PET) may be an effective and noninvasive means of identifying early in the course of endocrine, or hormone-based, therapy which patients will respond well to treatment. 

In a recent study, mice with mammary cell lines derived from breast tumors that were positive for estrogen receptor-alpha (ERα) and for progesterone receptor (PR) underwent small-animal (PET)/computed tomography (CT). 18F-fluoroestradiol (18F-FES)-PET was used to image ER status, 18F-fluoro furanyl norprogesterone (18F-FFNP)-PET was used to image PR status, and 18F-fluorodeoxyglucose (18F-FDG)-PET was used to image glucose uptake.

“PET has typically been used to identify the target for endocrine therapy in breast cancer by demonstrating that ER is present in tumors using [18F-FES-PET] or by monitoring for hormone-induced changes in tumor metabolism—“metabolic flare”—with [18F-FDG-PET] once therapy has begun,” explained the study's lead author, Amy M. Fowler, MD, PhD, of the Mallinckrodt Institute of Radiology at the Washington University School of Medicine in St. Louis, Missouri, in a statement issued by the Society of Nuclear Medicine. (Fowler's group's results were published in The Journal of Nuclear Medicine [2012;53(7):1119-1126], a publication of the Society of Nuclear Medicine.) “What is novel about our study is that we chose to image progesterone receptor levels to see how the estrogen signaling pathway is functioning in response to endocrine therapy.”

Primary mammary tumors and implanted tumors from the SSM2 and SSM3 mammary cell lines showed high uptake of 18F-FES and 18F-FFNP, and were confirmed to be ERα-positive and PR-positive. Classic estrogen-induced regulation of the PR gene was demonstrated by increased 18F-FFNP uptake of estradiol-treated SSM3 tumors.

Treatment with fulvestrant decreased 18F-FFNP, 18F-FES, and 18F-FDG uptake and inhibited growth of SSM3 tumors, but decreased only 18F-FES uptake in SSM2 tumors, with no effect on growth despite the fact that like the SSM3 tumors, the SSM2 tumors were also ERα-positive and PR-positive. Decreased 18F-FFNP uptake by SSM3 tumors occurred early after the start of therapy, before measurable tumor growth inhibition.

The results served to identify a profile that distinguished fulvestrant-sensitive from fulvestrant-resistant ERα-positive/PR-positive tumors before changes in tumor size, summarized the researchers. They added that based on this work, noninvasive imaging of baseline tumoral 18F-FES uptake and initial changes in 18F-FFNP uptake is a potentially useful strategy for identifying responders and nonresponders to endocrine therapy at an early stage.

Share this article:
You must be a registered member of ONA to post a comment.

Next Article in Web Exclusives

Sign Up for Free e-newsletters

What is this?

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Presence of uterine cancers examined among women at the time of hysterectomy ...

Among women undergoing a minimally invasive hysterectomy using electric power morcellation, uterine cancers were present in 27 per 10,000 women at the time of the procedure, according to a new study.

New approach identifies cancer mutations as targets of effective melanoma immunotherapy

A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy.

No change seen in breast cancer detection despite increased Medicare costs for ...

Breast cancer screening costs for Medicare patients skyrocketed between 2001 and 2009, but the increase did not lead to earlier detection of new breast cancer cases, according to a study.